Bio-Reference Laboratories (BRLI +5.4%) gains after reporting Q3 results that beat estimates by a slim margin. The embattled firm says it expects to increase net revenues by more than 15% and net income by around 20% in 2012.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs